Growth Hormone Biology: The Axis Behind Semax, NAD+, and Metabolic Peptide Research

Growth hormone (GH — the 191 amino acid peptide hormone produced by somatotroph cells in the anterior pituitary; the master regulator of somatic growth, body composition, metabolism, and tissue repair; declines progressively after age 30 through a process called somatopause — the age-related decline in GH secretion and GH/IGF-1 axis activity that contributes to the body composition changes, reduced energy, and impaired repair capacity of aging) operates as the central node in a multi-level endocrine axis.

At the top of the axis is the hypothalamus, which sends two opposing signals to the pituitary: GHRH (growth hormone releasing hormone — the 44 amino acid stimulatory hypothalamic peptide that binds GHRH receptors on somatotrophs to promote GH synthesis and release) and somatostatin (the 14 or 28 amino acid inhibitory hypothalamic peptide that tonically restrains GH release; the balance between GHRH and somatostatin determines the basal GH secretion rate). GH is secreted in pulses — a pattern critical for its biological activity — with the largest pulses occurring during slow-wave sleep.

GH acts on peripheral tissues both directly (through JAK2-STAT5 signaling in liver, muscle, and adipose) and indirectly through IGF-1 (insulin-like growth factor 1 — the primary effector of GH's anabolic and growth-promoting effects; synthesized primarily in the liver in response to GH signaling; circulates bound to IGF binding proteins (IGFBPs) that modulate its bioavailability and half-life). The GH pulse pattern matters: IGF-1 production by the liver is proportional to GH exposure, but it is the pulsatile GH pattern rather than sustained low-level exposure that produces optimal anabolic signaling.

The traditional model of GH regulation focused on the GHRH-somatostatin balance. This model was significantly revised with the discovery of ghrelin (the 28 amino acid peptide produced by stomach X/A cells; the endogenous agonist for the GHS-R1a (growth hormone secretagogue receptor 1a — a GPCR expressed on somatotrophs, hypothalamic neurons, and multiple other tissues; the target for synthetic GH secretagogues like GHRP-2, GHRP-6, and Ipamorelin)). Ghrelin represents an entirely separate stimulatory pathway for GH release.

The GHRH and ghrelin pathways are not independent — they show substantial synergy. Combined GHRH and ghrelin/GHS-R agonist administration produces GH releases that are much larger than either stimulus alone, consistent with the two pathways converging to amplify the pituitary GH release signal. This synergy is the mechanistic rationale for research strategies that target both pathways simultaneously.

Aging affects both pathways differently. Published research shows that hypothalamic GHRH output declines with age, and pituitary sensitivity to GHRH decreases. Simultaneously, somatostatin tone may increase with age, further restraining GH release. The ghrelin pathway also declines, with published data showing reduced GHS-R expression and reduced ghrelin secretion in aged individuals. This multi-level decline of the GH axis is mechanistically more complex than simple GHRH deficiency.

Somatotrophs (the GH-secreting cells of the anterior pituitary; comprising approximately 50% of all anterior pituitary cell types; organized in a patterned three-dimensional network that allows coordinated pulsatile GH secretion in response to hypothalamic signals) are not simple GH factories. They are highly regulated secretory cells whose output is determined by a complex integration of stimulatory (GHRH, ghrelin, estrogen) and inhibitory (somatostatin, IGF-1 feedback, cortisol, glucose) signals.

The pulsatile nature of GH secretion from somatotrophs is mechanistically important for peripheral tissue responses. Published research has demonstrated that the liver IGF-1 production response to GH is pulse-amplitude sensitive: larger GH pulses drive proportionally greater IGF-1 synthesis. The GH receptor on hepatocytes is transiently desensitized after each GH pulse — preventing continuous GH exposure from maintaining maximal receptor signaling. This means that approaches that increase GH secretion by amplifying pulse amplitude (through GHRH or ghrelin agonism) are more effective at increasing IGF-1 than approaches that produce a sustained low-level increase in GH.

Somatotroph number and function decline with age. Published histological data shows reduced somatotroph density in the anterior pituitary of aged humans. However, published studies also show that aged pituitary glands retain substantial GH synthesis capacity — the decline in GH secretion is predominantly a regulatory problem (impaired stimulation and excessive inhibition) rather than a failure of somatotroph production capacity. This regulatory vulnerability is the mechanistic opportunity for secretagogue approaches.

IGF-1 acts through the IGF-1 receptor (IGF1R — a receptor tyrosine kinase closely related to the insulin receptor; mediates the growth, proliferation, and survival signaling downstream of GH-induced hepatic IGF-1 production) in an endocrine (systemic, via circulating IGF-1), paracrine (locally produced IGF-1 acting on neighboring cells), and autocrine (locally produced IGF-1 acting on the producing cell) manner. This multi-mode action means that locally produced IGF-1 in tissues like muscle and bone has biological effects independent of hepatic (liver-produced) IGF-1 levels.

IGF binding proteins (IGFBPs 1-6 — a family of secreted proteins that bind IGF-1 and IGF-2 in circulation and in tissues; modulate IGF-1 bioavailability, half-life, and cellular access; IGFBP-3 is the primary circulating carrier protein) are a critical but often underappreciated component of the system. Circulating total IGF-1 levels do not necessarily reflect IGF-1 bioavailability at tissues — IGFBP levels, proteolysis of IGFBPs, and cell surface IGFBP interactions determine how much IGF-1 reaches and activates receptors.

The age-related decline in IGF-1 is well-documented: published cross-sectional data in humans shows a mean IGF-1 decline of approximately 14% per decade after age 20. This decline tracks with the somatopause and is associated with the body composition changes (reduced lean mass, increased fat mass) and reduced tissue repair capacity that characterize normal aging. Whether restoring IGF-1 to youthful levels is beneficial, neutral, or harmful in old age is genuinely complex — published epidemiological data shows both associations of high IGF-1 with longevity and associations with cancer risk, depending on the population and context studied.

Semax (the synthetic heptapeptide MEHFPGP — an analog of the ACTH(4-7) sequence with the proline-glycine-proline extension; developed at the Russian Institute of Molecular Genetics; registered as a drug in Russia and Ukraine for ischemic stroke and cognitive impairment) has documented interactions with the hypothalamic-pituitary-adrenal (HPA) axis that are relevant to GH axis function. The ACTH sequence from which Semax is derived acts not only on adrenal steroidogenesis but also on pituitary biology.

Published research on Semax documents elevation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the brain following intranasal administration. These neurotrophic factors have complex interactions with the GH axis at the hypothalamic level: BDNF signaling in the hypothalamus influences GHRH release, and the GH axis has bidirectional interactions with the neurotrophic factor milieu of the brain.

Semax's connection to the GH axis is therefore indirect — operating through hypothalamic neurotrophic modulation rather than direct GH secretagogue activity. This distinguishes Semax mechanistically from GHRP peptides (which directly activate GHS-R1a on somatotrophs) and positions it in a different research space: studying how central neurotrophic signaling influences the GH axis, rather than how direct pituitary stimulation alters GH output.

NAD+ and the sirtuin system interact with GH/IGF-1 signaling through multiple points. SIRT1 (activated by NAD+ and known to interact with multiple metabolic regulatory pathways) deacetylates and regulates STAT5b (the primary transcription factor downstream of GH receptor activation; required for GH-driven IGF-1 gene expression in liver) — suggesting that SIRT1 activity may modulate the hepatic sensitivity to GH signaling.

Published metabolic research has shown that insulin resistance and metabolic syndrome are associated with GH resistance — the condition in which circulating GH is normal or even elevated but IGF-1 is paradoxically low, due to impaired hepatic GH receptor signaling. NAD+ restoration, by supporting SIRT1 activity and improving insulin sensitivity, may improve hepatic GH receptor signaling and thus increase IGF-1 production at the same circulating GH level.

MOTS-c's AMPK activation also connects to GH axis function: AMPK regulates insulin signaling, glucose metabolism, and mitochondrial function in liver hepatocytes — all of which influence GH receptor sensitivity. A metabolically healthy hepatocyte responds more effectively to the GH pulse that drives IGF-1 synthesis. This pathway makes metabolic peptide research relevant to GH axis function even without direct GHS-R agonism.

Researchers interested in GH axis endpoints should distinguish between studies targeting GH secretion (requiring measurement of pulsatile GH — which is challenging due to the short half-life of GH and pulsatile secretion pattern), IGF-1 production (more stable, can be measured from single blood samples), GH receptor signaling (requiring STAT5b phosphorylation assays in target tissues), and downstream anabolic endpoints (lean mass, bone density, tissue repair markers).

For studies using Semax in GH axis research, intranasal administration at published doses (typically 200–900 µg intranasally) provides the most direct precedent from published research. Combining Semax with direct GHRH or GHS-R agonists to study HPA-GH interactions would represent an experimental approach with mechanistic logic but limited published precedent.

For studies examining NAD+ or MOTS-c effects on GH axis sensitivity, the recommended endpoint focus is on IGF-1 and IGFBP-3 (the most stable and accessible markers of GH axis activity), with STAT5b phosphorylation in liver tissue (from biopsy or rodent sacrifice models) providing mechanistic depth. Randomized crossover designs with washout periods are most appropriate for studying the metabolic modulation of GH sensitivity.

Researchers studying the GH/IGF-1 axis, hypothalamic-pituitary biology, and metabolic signaling can review Semax, NAD+, and MOTS-c product specifications at Blackwell BioLabs. All batches are verified by third party testing with HPLC purity confirmation and mass spectrometry identity verification on every lot.